Radioimmunotherapy Of Lymphoma Research Articles

Radioimmunotherapy of solid tumors: a review "of mice and men".

Radioimmunotherapy in lymphoma is crossing the threshold to become a standard mode of treatment. Whereas in solid tumors in preclinical studies, radioimmunotherapy has proven to be superior to conventional chemotherapy, clinical success is still limited. The purpose of this brief review is to analyze recent developments in preclinical as well as clinical radioimmunotherapy of solid, CEA-expressing tumors. Advances in experimental radioimmunotherapy are characterized by the development of metastatic, rather than subcutaneous, tumor models in nude mice, which seem to reflect the actual clinical situation much more accurately. Furthermore, the recent development of strategies to reduce the renal accretion of antibody fragments and peptides enables the use of such smaller molecules for therapy, especially those also labeled with radiometals and other forms of intracellularly retained radionuclides. Recent developments in clinical radioimmunotherapy are characterized by a trend toward the treatment of small-volume and micrometastatic disease, as is the case, e.g., in adjuvant settings. Interestingly, despite dramatic differences in size, weight and percent-of-injected-dose-per-gram uptake values, only small differences between animal models and the actual patient situation exist with respect to activity concentrations (in microCi/gram) in the tumors and tissues. Because the activity concentration over time determines the radiation absorbed dose, and thus biological effects, we postulate that animal models should be able to predict actual clinical scenarios fairly well. These findings could be used as guidelines in the design of future preclinical, as well as clinical, trials.

Carcinoembryonic Antigen as a Target Cancer Antigen for Radiolabeled Antibodies: Prospects for Cancer Imaging and Therapy

This paper reviews the development of cancer imaging with radiolabeled antibodies to carcinoembryonic antigen and the current status and challenges for cancer therapy with radiolabeled antibodies. Advances in antibody preparations, choice of isotope and labeling methods, as well as imaging methods have resulted in rapid and sensitive radioimmunodetection agents that can affect the management of cancer patients. Radioimmunotherapy faces other problems, but advances in antibody engineering and control of dose-limiting myelotoxicity may result in reproducible clinical responses similar to the encouraging results being obtained in the radioimmunotherapy of lymphomas.

Radioimmunotherapy of lymphoma.

The development of radiolabeled monoclonal antibodies (MoAb) was a significant advance in the use of these molecules for the treatment of human neoplasms. Unlabeled murine MoAbs had proven to have modest activity against human neoplasms due to (1) the relatively poor interactions between the antibody Fc receptors and human effector cells, and (2) the lack of uniform antigen expression within tumors [1,2]. The combination of toxic radioisotopes with a specific targeted MoAb delivery system provided a novel way to overcome these obstacles. A variety of clinically significant responses have now been witnessed. In this chapter we will discuss the therapeutic trials conducted previously to illustrate the features of radiolabeled immunoconjugates, mention new obstacles to successful incorporation of radiolabeled MoAbs into standard oncologic therapy, and suggest future directions that may lead to enhanced effectiveness of radioimmunoconjugates.KeywordsAutologous Bone MarrowTumor Antigen ExpressionJohns Hopkins OncologyHuman Effector CellTumor PenetranceThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Radiobiologic basis of lymphoma radio-immunotherapy

Radiobiologic basis of lymphoma radio-immunotherapy